On May 22, 2026 Inocras, a bioinformatics-led company harnessing the power of whole-genome data and proprietary analytics to deliver curated insights, reported that new real-world evidence evaluating whole-genome sequencing-based homologous recombination deficiency phenotyping has been accepted for online publication at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The abstract, titled "Whole-genome HRD phenotyping as a predictor of PARP inhibitor benefit in first-line maintenance high-grade serous ovarian cancer," reports findings from a collaborative study between Inocras and the Severance Hospital gynecologic oncology team, one of Inocras’s major clinical partners in Korea.

Using matched tumor-normal whole-genome sequencing through CancerVision, investigators evaluated 84 patients with high-grade serous ovarian cancer who received PARP inhibitor maintenance therapy in either the first-line or second-line maintenance setting. The study assessed whether WGS-based HRD indicators, or CancerVision’s WGS-HRD, correlated with clinical outcomes following PARP inhibitor therapy.

Patients classified as WGS-HRD-positive had a longer median progression-free survival than those classified as WGS-HRD-negative, with an overall mPFS of 27.5 months versus 12.0 months. The association was most pronounced in the first-line maintenance setting, where WGS-HRD positive patients had an mPFS of 44.2 months versus 10.0 months. In the second-line maintenance setting, no significant difference in survival was observed based on HRD status, suggesting the predictive value of WGS-HRD may be strongest in earlier treatment settings.

The study also found that 21.4% of patients were WGS-HRD positive despite lacking BRCA mutations, underscoring the potential of WGS-HRD to identify patients who may not be captured by BRCA testing alone. Compared with the conventional scarHRD method, WGS-HRD demonstrated higher predictive value in clinical prognosis and PARP inhibitor responsiveness. The study adds to Inocras’ growing body of evidence supporting CancerVision as a comprehensive whole-genome sequencing platform for precision oncology.

"These findings provide important real-world evidence that whole-genome HRD scoring can advance how we identify ovarian cancer patients most likely to benefit from PARP inhibitor maintenance therapy," said Jehee Suh, CEO of Inocras. "CancerVision is a comprehensive WGS-based clinical analysis platform, and these data highlight its potential to enhance clinical decision-making."

"The first-line maintenance findings are particularly encouraging because they suggest that WGS-based HRD assessment may refine current BRCA- and genomic-scar–based approaches for identifying patients most likely to derive durable benefit from PARP inhibitor maintenance therapy," said Joonoh Lim, Physician Scientist at Inocras, who led the study in collaboration with Severance Hospital. "These findings add to the growing evidence base for whole-genome HRD assessment, and we look forward to prospective validation."

Abstract Details

Title: Whole-genome HRD phenotyping as a predictor of PARP inhibitor benefit in first-line maintenance high-grade serous ovarian cancer.
Format: Online publication / Online-only abstract
Abstract Number: e17608
Publication Date/Time: May 21 at 05:00 PM ET
Authors: Joonoh Lim, MD, PhD, Inocras Inc., San Diego, CA
Session/Category: Gynecologic Cancer

(Press release, Inocras, MAY 22, 2026, View Source [SID1234666021])

On May 22, 2026 Formosa Pharmaceuticals, Inc. reported that its abstract highlighting the differentiated binding profile and preclinical efficacy of TSY-310, a novel bispecific antibody-drug conjugate (ADC), has been selected for presentation at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, to be held May 29 – June 2, 2026, in Chicago, Illinois. TSY-310 simultaneously targets EGFR and ROR1, two receptors frequently co-expressed in prevalent solid tumors. By leveraging a unique bispecific modality, TSY-310 optimizes target engagement and intracellular delivery, facilitating a potent bystander effect to address the challenges of tumor heterogeneity.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details

Title: TSY-310, A Novel Bispecific EGFR x ROR1 ADC, Exhibits Potent Antitumor Activity in Heterogeneous Breast Tumors Through Enhanced Internalization and Bystander Cytotoxicity
Session: Developmental Therapeutics: Molecularly Targeted Agents and Tumor Biology
Date & Time: May 30, 2026, 1:30 pm – 4:30 pm CT
Abstract Number: 3086
Poster Number: 223
Presenter: Dr. Kuo-Ming Yu, Ph.D., Director, CMC and Production

Highlights

Superior Selectivity: Bispecific binding, enhancing internalization specifically in tumor cells co-expressing EGFR and ROR1.
Enhanced Payload Delivery: Evidence of efficient lysosomal trafficking and the subsequent release of the cytotoxic payload.
Bystander Efficacy: Eradication of neighboring antigen-negative tumor cells, a critical factor in treating complex, heterogeneous tumor environments.

"Our participation at ASCO (Free ASCO Whitepaper) is an acknowledgement of the program’s potential as a worthy contributor to the future oncology treatment landscape," said Erick Co, President & CEO of Formosa Pharmaceuticals. "We are eager to place TSY-310 in the toolbox of oncologists and patients who face the evolving challenges with traditional single-target therapies."

Full abstract and presentation details will be available through ASCO (Free ASCO Whitepaper) and corporate websites in accordance with the meeting’s policies.

About TSY-310: TSY-310 is a next-generation bispecific ADC targeting EGFR and ROR1. By achieving high-affinity target recognition through an efficient, simplified protein architecture, TSY-310 aims to provide a durable, "best-in-class" therapeutic option for patients with advanced solid tumors, including Non-Small Cell Lung Cancer (NSCLC).

(Press release, Formosa Pharmaceuticals, MAY 22, 2026, View Source [SID1234665926])

On May 22, 2026 Alligator Bioscience (Nasdaq Stockholm: ATORX) today comments on a recent update shared by Shanghai Henlius Biotech, Inc. regarding long-term follow-up observations from clinical studies of HLX22.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

According to Henlius’ communication, long-term follow-up over more than 39 months indicates that patients treated with HLX22 continue to demonstrate extended progression-free survival (PFS) at the current observation point. The update reflects ongoing follow-up and does not include new numerical efficacy data.

HLX22 is an innovative anti-HER2 monoclonal antibody that has been granted orphan drug designation in both the U.S. and EU for gastric cancer and is being developed by Henlius under a license from AbClon, Inc., following a discovery collaboration which grants Alligator the right to participate in potential future revenues.

"We view Henlius’ update on the long-term follow-up of HLX22 as further evidence of the continued clinical development of the program," said Søren Bregenholt, CEO of Alligator Bioscience. "Sustained follow-up across studies is an important part of building the overall understanding of a molecule’s profile, and we note Henlius’ ongoing efforts to advance HLX22 across multiple indications."
Under the terms of Alligator’s agreement with AbClon, Alligator is entitled to 35% of AbClon’s revenue from its sublicense to Henlius, including potential milestone payments and royalty revenues, which, if HLX22 is successfully developed and approved, could represent a meaningful long-term revenue opportunity for Alligator.

(Press release, Alligator Bioscience, MAY 22, 2026, View Source [SID1234666006])

On May 22, 2026 PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, reported five upcoming presentations at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting and European Hematology Association (EHA) (Free EHA Whitepaper) 2026 Congress. The ASCO (Free ASCO Whitepaper) annual meeting will be held May 29-June 2 in Chicago, and the EHA (Free EHA Whitepaper)2026 Congress will be held June 11-14 in Stockholm, Sweden.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

PharmaEssentia will present new analyses from the Phase 3 SURPASS-ET study (NCT04285086) of ropeginterferon alfa-2b in patients with essential thrombocythemia (ET), including two-year outcomes comparing early versus delayed initiation (continuous treatment from baseline vs. initiation following prior anagrelide therapy) and post-hoc analyses of patients who transitioned from anagrelide. Ropeginterferon alfa-2b-njft is currently FDA-approved and marketed as BESREMi for the treatment of adults with polycythemia vera (PV). The use of ropeginterferon alfa-2b-njft for ET is currently still investigational, but it is currently under review by FDA with a PDUFA goal date of August 30, 2026.

Findings from SURPASS-ET demonstrate sustained hematologic control and progressive molecular improvement with longer interferon exposure, with deeper molecular responses and improved long-term disease control observed with earlier initiation. Patients who transitioned from anagrelide showed improved hematologic parameters over 12 weeks, supporting the feasibility of treatment transition. Importantly, estimated progression-free survival (PFS) at 24 months was 76.9% in patients who received ropeginterferon alfa-2b from baseline compared to 43.1% in those with delayed initiation. Together, these data support consideration of earlier ropeginterferon alfa-2b use in high-risk ET following hydroxyurea intolerance or resistance.

PharmaEssentia will also present an integrated analysis of the SURPASS-ET and Phase 2b EXCEED-ET (NCT05482971) trials. The analysis includes 182 patients across both studies and evaluates the consistency of clinical benefit across treatment lines, including treatment-naïve and previously treated populations, as well as across molecular subtypes and ethnicities. Results demonstrated clinically meaningful hematologic and molecular responses in both treatment-naïve and pretreated patients. Efficacy was consistent across driver mutation subtypes, and the presence of additional non-driver mutations did not adversely impact outcomes.

"These findings represent an important step forward in understanding the potential use of interferon-based approaches in essential thrombocythemia," said Ruben Mesa, M.D., co-principal investigator, presenting author, and President of Advocate Health Cancer National Service Line. "Together, these data continue to build on the growing body of evidence supporting the use of ropeginterferon alfa-2b in ET and reinforce its potential role as a meaningful treatment option for patients."

In addition, PharmaEssentia will present real-world data evaluating the association between neutrophil-to-lymphocyte ratio (NLR) and thrombotic risk in 11,809 U.S. veterans with PV. An online-only abstract will also report findings from a meta-analysis evaluating dosing strategies for ropeginterferon alfa-2b in PV, suggesting that a higher initial dose with accelerated titration (HIDAT) may lead to improved early hematologic and molecular response rates compared to lower-dose currently approved regimens.

ASCO
Poster Presentations

Title: Integrated Analysis of the Ropeginterferon alfa-2b Clinical Program in Essential Thrombocythemia to Demonstrate Molecular and Hematologic Responses with Safety Profile Across Treatment Lines, Ethnicities, and Driver Mutation Types
Abstract Number: 6576
Poster: 369
Presenter: Ruben Mesa, M.D.
Session: Hematologic Malignancies – Leukemia, Myelodysplastic Syndromes, and Allotransplant
Date: June 1st
Time: 9-12 pm CDT

Title: Association of neutrophil‑to‑lymphocyte ratio and thrombotic events in US Veterans with Polycythemia vera
Abstract Number: 6578
Poster: 371
Presenter: Ying Wang, PhD
Session: Hematologic Malignancies – Leukemia, Myelodysplastic Syndromes, and Allotransplant
Date: June 1st
Time: 9-12 pm CDT

Published Abstract

Title: Effect of Higher Initial Dose and Accelerated Titration of Ropeginterferon Alfa-2b on Early Hematologic and Molecular Responses in Polycythemia Vera: A Meta-Analysis
Abstract Number: e18592

EHA
Oral Presentation
Title: Early versus Delayed Initiation of Ropeginterferon Alfa-2b in High-Risk Essential Thrombocythaemia: Two-Year Results from the Phase 3 SURPASS-ET Study
Abstract Number: S219
Presenter: Harry Gill, M.D.
Session: Myeloproliferative neoplasms – Clinical
Date: June 13th
Time: 5:15 – 6:30 pm CEST

Poster Presentations

Title: Ropeginterferon alfa-2b Demonstrates Molecular and Hematologic Responses with a Favorable Safety Profile in Essential Thrombocythemia
Abstract Number: PS1986
Presenter: Harry Gill, M.D.
Session: Myeloproliferative neoplasms – Clinical
Date: June 13th
Time: 6:45 – 7:45 pm CEST

Title: Hematologic Control and Improved Safety Following Switch from Anagrelide to Ropeginterferon Alfa-2b in Patients with Essential Thrombocythemia: 12-Week Pre-/Post-Switch Analysis from the SURPASS-ET study
Abstract Number: PF912
Presenter: Lucia Masarova, M.D.
Session: Myeloproliferative neoplasms – Clinical
Date: June 12th
Time: 6:45 – 7:45 pm CEST

(Press release, PharmaEssentia, MAY 22, 2026, View Source [SID1234666022])

On May 22. 2026 ClearNote Health, a company dedicated to improving early detection for some of the deadliest cancers, reported it will present new multi-cohort validation data for its Avantect Pancreatic Cancer Test at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, taking place in Chicago May 29 – June 2.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ASCO attendees are invited to meet with ClearNote Health’s scientific and medical leadership team, including newly appointed Chief Medical Officer Jeffrey Venstrom, MD, and Chief Scientific Officer Samuel Levy, PhD, to discuss the company’s latest clinical data, strategic commercialization progress, and vision for advancing early cancer detection.

"Pancreatic cancer remains one of the most lethal malignancies because it is often diagnosed too late for curative intervention," said Dr. Venstrom. "We are excited to share new validation data at ASCO (Free ASCO Whitepaper) demonstrating the strong performance of our Avantect Pancreatic Cancer Test among individuals with elevated risk. This test complements existing diagnostic and risk assessment strategies and provides clinically actionable insights when earlier detection can make the greatest difference."

During the 2026 ASCO (Free ASCO Whitepaper) Annual Meeting, ClearNote Health will present results from an independent validation cohort of 1,445 individuals with multiple risk factors, including type 2 diabetes, family history, and genetic predisposition to pancreatic cancer. In this cohort, the Avantect Pancreatic Cancer Test demonstrated industry-leading performance, achieving 82.6% overall sensitivity, 76.8% sensitivity for early-stage (Stage I–II) disease, and 97.5% specificity. Two additional validation cohorts totaling 338 individuals showed consistently robust performance of Avantect in individuals enriched for new onset type 2 diabetes, further supporting its performance in clinically relevant populations with elevated risk.

"Our enhanced Avantect test combines a rich set of signals from epigenomic, fragmentomic, and genotyping sources in concert with glycan-specific measures into a multimodal cancer detection model. The precision of cancer detection achieved with our Avantect test is reflected in these validation results," said Dr. Levy.

Featured Presentation

Multi-cohort validation of a multi-analyte liquid biopsy test for early-stage pancreatic cancer detection
Abstract / poster number: 4139 / 122
Presenter: Anna Bergamaschi, PhD, ClearNote Health
Session: Gastrointestinal Cancer
Location: Hall A – Posters and Exhibits
Date and time: Saturday, May 30, 2026, 9:00 am – 12:00 pm CDT

Designed as a simple blood test, the Avantect Pancreatic Cancer Test is intended for patients with known genetic predispositions, a family history of pancreatic cancer, or those age 50 or older who have been newly diagnosed with type 2 diabetes. By evaluating multiple cancer-associated signals together, ClearNote Health’s approach provides meaningful context for care discussions. The next-generation test is being used in the Surveillance of pAncreatic health aFter diabEtes Diagnosis (SAFE-D) study led by the NHS in the UK — one of the world’s largest projects evaluating pancreatic cancer detection in individuals with new-onset diabetes. The test is also being incorporated into the international Pancreatic Cancer Early Detection (PRECEDE) Consortium, a global multi-center effort focused on advancing earlier diagnosis and risk-stratified screening for people with familial or genetic risk for pancreatic cancer.

To learn more about ClearNote Health’s planned activities at the 2026 ASCO (Free ASCO Whitepaper) Annual Meeting or to schedule a meeting, please visit View Source

(Press release, ClearNote Health, MAY 22, 2026, View Source [SID1234666023])